ArticleFrontiers in oncology2025
Identification of unique biomarkers in colorectal cancer based on comprehensive analysis and machine learning.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Colorectal cancer (CRC) is a common malignant tumor with high incidence and poor prognosis. Identifying effective biomarkers is crucial for its diagnosis and treatment. Methods: Gene expression data were obtained from TCGA-CRC and GSE39582 datasets. After preprocessing, differentially expressed genes (DEGs) were screened using the limma package. Hub genes were identified via WGCNA, miRNA-hub/TF-hub gene network construction, and LASSO, SVM-RFE, and random forest algorithms. Subtype analysis, survival analysis, external validation, qRT-PCR, Western blot, and ferroptosis-related assays were performed. Results: Fourteen ferroptosis-mitochondria-RBP-related genes (IMRBPs) were identified, including seven hub RBP genes (APEX1, BRCA1, DNMT1, EZH2, PTTG1, SND1, UHRF1). APEX1 was downregulated in CRC, while the other six were upregulated. The diagnostic model based on these seven genes showed high AUC values (0.818-0.924) in multiple datasets. These hub genes were associated with ferroptosis suppression by regulating GSH/GSSGand Fe²⁺ levels. Discussion: The seven hub RBP genes are potential biomarkers for CRC, providing new insights and therapeutic targets. However, functional validation and larger sample sizes are needed for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.